Is Dyne Therapeutics Stock a Good Investment?
Dyne Therapeutics Investment Advice | DYN |
- Examine Dyne Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Dyne Therapeutics' leadership team and their track record. Good management can help Dyne Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Dyne Therapeutics' business and its evolving consumer preferences.
- Compare Dyne Therapeutics' performance and market position to its competitors. Analyze how Dyne Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if Dyne Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Dyne Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Dyne Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Dyne Therapeutics is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Very Weak | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Very Low | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Dyne Therapeutics Stock
Researching Dyne Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 100.0% of the company shares are held by institutions such as insurance companies. The book value of Dyne Therapeutics was currently reported as 6.93. The company has Price/Earnings To Growth (PEG) ratio of 0.19. Dyne Therapeutics recorded a loss per share of 3.62. The entity last dividend was issued on the May 30, 2002. The firm had 1:5 split on the May 25, 2010.
To determine if Dyne Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Dyne Therapeutics' research are outlined below:
| Dyne Therapeutics generated a negative expected return over the last 90 days | |
| Dyne Therapeutics has high historical volatility and very poor performance | |
| Reported Net Loss for the year was (235.94 M) with profit before taxes, overhead, and interest of 0. | |
| Dyne Therapeutics has about 291.84 M in cash with (188.16 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.64. | |
| Over 100.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from thelincolnianonline.com: Dyne Therapeutics, Inc. Director Jason P. Rhodes Sells 782 Shares |
Dyne Therapeutics Quarterly Good Will |
|
Dyne Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Dyne Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Dyne Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 7th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 7th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Dyne Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Dyne Therapeutics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2017-12-31 | 2017-12-31 | -0.42 | -0.35 | 0.07 | 16 | ||
2023-03-02 | 2022-12-31 | -0.84 | -0.74 | 0.1 | 11 | ||
2021-05-06 | 2021-03-31 | -0.6 | -0.5 | 0.1 | 16 | ||
2022-11-03 | 2022-09-30 | -0.92 | -0.8 | 0.12 | 13 | ||
2023-10-30 | 2023-09-30 | -0.83 | -0.99 | -0.16 | 19 | ||
2024-03-05 | 2023-12-31 | -0.92 | -1.09 | -0.17 | 18 | ||
2022-05-02 | 2022-03-31 | -0.88 | -0.69 | 0.19 | 21 | ||
2021-11-04 | 2021-09-30 | -0.64 | -0.83 | -0.19 | 29 |
Know Dyne Therapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Dyne Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Dyne Therapeutics backward and forwards among themselves. Dyne Therapeutics' institutional investor refers to the entity that pools money to purchase Dyne Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Tcg Crossover Management, Llc | 2024-09-30 | 2.7 M | T. Rowe Price Associates, Inc. | 2024-06-30 | 2.4 M | Vr Adviser, Llc | 2024-06-30 | 2.2 M | Goldman Sachs Group Inc | 2024-06-30 | 2.1 M | Holocene Advisors, Lp | 2024-06-30 | 2.1 M | Geode Capital Management, Llc | 2024-06-30 | 1.8 M | Franklin Resources Inc | 2024-06-30 | 1.7 M | Sofinnova Ventures | 2024-06-30 | 1.6 M | Artal Group S A | 2024-06-30 | 1.5 M | Fmr Inc | 2024-09-30 | 9 M | Fcpm Iii Services Bv | 2024-06-30 | 7.8 M |
Dyne Therapeutics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a total capitalization of 3.05 B.Market Cap |
|
Dyne Therapeutics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (1.43) | (1.36) | |
| Return On Capital Employed | (2.12) | (2.02) | |
| Return On Assets | (1.43) | (1.36) | |
| Return On Equity | (2.58) | (2.46) |
Determining Dyne Therapeutics' profitability involves analyzing its financial statements and using various financial metrics to determine if Dyne Therapeutics is a good buy. For example, gross profit margin measures Dyne Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Dyne Therapeutics' profitability and make more informed investment decisions.
Evaluate Dyne Therapeutics' management efficiency
Dyne Therapeutics has Return on Asset of (0.4035) % which means that on every $100 spent on assets, it lost $0.4035. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.6868) %, meaning that it generated no profit with money invested by stockholders. Dyne Therapeutics' management efficiency ratios could be used to measure how well Dyne Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 21st of November 2024, Return On Tangible Assets is likely to grow to -1.36. In addition to that, Return On Capital Employed is likely to grow to -2.02. As of the 21st of November 2024, Debt To Assets is likely to grow to 0.26, while Total Assets are likely to drop about 156.8 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 1.53 | 1.45 | |
| Tangible Book Value Per Share | 1.53 | 1.45 | |
| Enterprise Value Over EBITDA | (3.00) | (2.85) | |
| Price Book Value Ratio | 8.70 | 9.13 | |
| Enterprise Value Multiple | (3.00) | (2.85) | |
| Price Fair Value | 8.70 | 9.13 | |
| Enterprise Value | 699.6 M | 465.6 M |
The strategic vision of Dyne Therapeutics management plays a critical role in its financial performance. By evaluating this vision, we provide insights into the stock's growth potential.
Beta 1.095 |
Basic technical analysis of Dyne Stock
As of the 21st of November, Dyne Therapeutics shows the Variance of 28.74, standard deviation of 5.36, and Mean Deviation of 3.15. Dyne Therapeutics technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices.Dyne Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Dyne Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Dyne Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Dyne Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Understand Dyne Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Dyne Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.06) | |||
| Market Risk Adjusted Performance | (0.19) | |||
| Mean Deviation | 3.15 | |||
| Coefficient Of Variation | (1,043) | |||
| Standard Deviation | 5.36 | |||
| Variance | 28.74 | |||
| Information Ratio | (0.11) | |||
| Jensen Alpha | (0.75) | |||
| Total Risk Alpha | (1.13) | |||
| Treynor Ratio | (0.20) | |||
| Maximum Drawdown | 32.99 | |||
| Value At Risk | (5.63) | |||
| Potential Upside | 5.7 | |||
| Skewness | (2.36) | |||
| Kurtosis | 16.01 |
| Risk Adjusted Performance | (0.06) | |||
| Market Risk Adjusted Performance | (0.19) | |||
| Mean Deviation | 3.15 | |||
| Coefficient Of Variation | (1,043) | |||
| Standard Deviation | 5.36 | |||
| Variance | 28.74 | |||
| Information Ratio | (0.11) | |||
| Jensen Alpha | (0.75) | |||
| Total Risk Alpha | (1.13) | |||
| Treynor Ratio | (0.20) | |||
| Maximum Drawdown | 32.99 | |||
| Value At Risk | (5.63) | |||
| Potential Upside | 5.7 | |||
| Skewness | (2.36) | |||
| Kurtosis | 16.01 |
Consider Dyne Therapeutics' intraday indicators
Dyne Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Dyne Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 47458.3 | |||
| Daily Balance Of Power | (0.17) | |||
| Rate Of Daily Change | 0.99 | |||
| Day Median Price | 30.1 | |||
| Day Typical Price | 29.98 | |||
| Price Action Indicator | (0.50) | |||
| Period Momentum Indicator | (0.26) | |||
| Relative Strength Index | 42.23 |
Dyne Therapeutics Corporate Filings
F4 | 18th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
8K | 12th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 8th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Dyne Stock media impact
Far too much social signal, news, headlines, and media speculation about Dyne Therapeutics that are available to investors today. That information is available publicly through Dyne media outlets and privately through word of mouth or via Dyne internal channels. However, regardless of the origin, that massive amount of Dyne data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Dyne Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Dyne Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Dyne Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Dyne Therapeutics alpha.
Dyne Therapeutics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Dyne Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Dyne Therapeutics Historical Investor Sentiment
Investor biases related to Dyne Therapeutics' public news can be used to forecast risks associated with an investment in Dyne. The trend in average sentiment can be used to explain how an investor holding Dyne can time the market purely based on public headlines and social activities around Dyne Therapeutics. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Dyne Therapeutics' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Dyne Therapeutics and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Dyne Therapeutics news discussions. The higher the estimate score, the more favorable the investor's outlook on Dyne Therapeutics.
Dyne Therapeutics Corporate Management
| Romesh Subramanian | CoFounder Advisor | Profile | |
| Richard MBA | Senior Administration | Profile | |
| Ashish MBA | Chief Officer | Profile | |
| Oxana Beskrovnaya | Chief Officer | Profile | |
| Lucia Celona | Chief Officer | Profile | |
| Daniel Wilson | Senior Legal | Profile |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dyne Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. To learn how to invest in Dyne Stock, please use our How to Invest in Dyne Therapeutics guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dyne Therapeutics. If investors know Dyne will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dyne Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.62) | Return On Assets (0.40) | Return On Equity (0.69) |
The market value of Dyne Therapeutics is measured differently than its book value, which is the value of Dyne that is recorded on the company's balance sheet. Investors also form their own opinion of Dyne Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Dyne Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dyne Therapeutics' market value can be influenced by many factors that don't directly affect Dyne Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Dyne Therapeutics' value and its price, as these two are different measures arrived at by various means. Investors typically determine if Dyne Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dyne Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.